Lurasidone
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314232

CAS#: 367514-87-2 (free base)

Description: Lurasidone is a new atypical antipsychotic. I is also approved for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults when used alone or in combination with lithium or valproate. Lurasidone acts as an antagonist of the following sites: α1-adrenergic receptor (Ki = 48 nM); α2A-adrenergic receptor (Ki = 1.6 nM); α2C-adrenergic receptor (Ki = 10.8 nM); D1 receptor (Ki = 262 nM); D2 receptor (Ki = 1.7 nM); 5-HT2A receptor (Ki = 2.0 nM); 5-HT2C receptor (Ki = 415 nM); 5-HT7 receptor (Ki = 0.5 nM). And as a partial agonist of the following sites: 5-HT1A receptor (Ki = 6.8 nM). (Source: http://en.wikipedia.org/wiki/Lurasidone).


Chemical Structure

img
Lurasidone
CAS# 367514-87-2 (free base)

Theoretical Analysis

MedKoo Cat#: 314232
Name: Lurasidone
CAS#: 367514-87-2 (free base)
Chemical Formula: C28H36N4O2S
Exact Mass: 492.2559
Molecular Weight: 492.682
Elemental Analysis: C, 68.26; H, 7.37; N, 11.37; O, 6.49; S, 6.51

Price and Availability

Size Price Availability Quantity
1.0g USD 150.0 Same day
2.0g USD 250.0 Same day
5.0g USD 450.0 Same day
10.0g USD 750.0 Same day
50.0g USD 1950.0 Same day
200.0g USD 4650.0 2 Weeks
Bulk inquiry

Synonym: SM13496; SM-13496; SM 13496; SM13,496; SM-13,496; SM 13,496; Lurasidone, trade name: Latuda

IUPAC/Chemical Name: (3aR,4S,7R,7aS)-2-(((1R,2R)-2-((4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)cyclohexyl)methyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione

InChi Key: PQXKDMSYBGKCJA-CVTJIBDQSA-N

InChi Code: InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1

SMILES Code: C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O

Appearance: White to off-white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 492.682 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Woo YS, Wang HR, Bahk WM. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat. 2013;9:1521-9. doi: 10.2147/NDT.S51910. Epub 2013 Oct 8. Review. PubMed PMID: 24143101; PubMed Central PMCID: PMC3797281.

2: Tarazi FI, Riva MA. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia. Expert Opin Drug Discov. 2013 Oct;8(10):1297-307. doi: 10.1517/17460441.2013.815163. Epub 2013 Jul 10. Review. PubMed PMID: 23837554.

3: Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. Review. PubMed PMID: 23272794.

4: Sanford M. Lurasidone : in the treatment of schizophrenia. CNS Drugs. 2013 Jan;27(1):67-80. doi: 10.1007/s40263-012-0026-x. Review. PubMed PMID: 23264146.

5: Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther. 2012 Oct;29(10):815-25. doi: 10.1007/s12325-012-0052-6. Epub 2012 Sep 20. Review. PubMed PMID: 23001538.

6: De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. Review. PubMed PMID: 22900950.

7: Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. Review. PubMed PMID: 22849428.

8: Risbood V, Lee JR, Roche-Desilets J, Fuller MA. Lurasidone: an atypical antipsychotic for schizophrenia. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1033-46. doi: 10.1345/aph.1M721. Epub 2012 Jul 24. Review. PubMed PMID: 22828971.

9: Yasui-Furukori N. Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug Des Devel Ther. 2012;6:107-15. doi: 10.2147/DDDT.S11180. Epub 2012 May 8. Review. PubMed PMID: 22675261; PubMed Central PMCID: PMC3367402.

10: McIntyre RS, Cha DS, Alsuwaidan M, McIntosh D, Powell AM, Jerrell JM. A review of published evidence reporting on the efficacy and pharmacology of lurasidone. Expert Opin Pharmacother. 2012 Aug;13(11):1653-9. doi: 10.1517/14656566.2012.683174. Epub 2012 May 5. Review. PubMed PMID: 22559286.



Additional Information

related CAS#
367514-87-2 (Lurasidone free base); 367514-87-2 (Lurasidone HCl salt)